<DOC>
	<DOCNO>NCT01096329</DOCNO>
	<brief_summary>The purpose study determine absorption testosterone spray Intrinsa® Patch .</brief_summary>
	<brief_title>A Pharmacokinetic ( PK ) Study Compare Absorption Two Formulations Transdermal Testosterone Spray Intrinsa®</brief_title>
	<detailed_description />
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>1 . Written Informed Consent 2 . Naturally surgically postmenopausal female , 45 65 year age 3 . Subjects spontaneous amenorrhea least 12 month 4 . Subjects serum total testosterone level &lt; 30 ng/dL 5 . Subjects currently stable dose prescribed oral transdermal estrogen replacement therapy ( ERT ) period least 8 12 week prior screen , respectively , ERT . 6 . A body weight least 50 kg body mass index ( BMI ) 18 35 kg/m2 , inclusive [ BMI calculate weight kg/ ( height ) 2 ] 7 . Medically healthy , clinically insignificant screen result ( e.g. , laboratory profile , medical history , ECGs , physical examination ( include breast examination ) , opinion Investigator . 8 . Subjects able communicate Investigator , understand comply requirement study participation . 9 . An adequate washout period prior obtain baseline assessment woman previously treat postmenopausal symptom . Calculated study Day 1 , minimum washout period 2 4 week prior treatment testosterone oral transdermal product , respectively , 3 month prior treatment testosterone implant 2 week treatment estratest . 1 . A positive serum pregnancy test screen 2 . A history presence significant cardiovascular , neurological , hematological , psychiatric , hepatic , gastrointestinal , pulmonary , endocrine , immunologic renal disease condition know interfere transdermal absorption , distribution , metabolism , excretion drug place subject increase risk determine Investigator 3 . Any clinically significant laboratory abnormality judge Investigator 4 . Subjects experience &gt; 20 hot flush per week 5 . Subjects suffer severe acne , moderate severe hirsutism androgenic alopecia , history severe dermatological problem druginduced contact dermatitis 6 . Systolic blood pressure &gt; 150 mm Hg diastolic blood pressure &gt; 95 mm Hg screen prior first dose study ( two rechecks allow ) 7 . Any malignancy except basal cell carcinoma 8 . A significant psychiatric disorder ( e.g. , major depression , etc . ) might , Investigator 's opinion , prevent subject complete study 9 . Currently smoke 10 cigarette day 10 . A history breast biopsy atypical hyperplasia 11 . A prior history breast cancer , suspect breast cancer , current prior cancer within past 10 year 12 . Exhibits anemia , define hemoglobin level screen laboratory 's low limit normal reference range 13 . Diabetes mellitus 14 . Any chronic skin disorder ( e.g. , eczema , psoriasis ) likely interfere transdermal drug absorption assessment skin tolerability 15 . Positive urine drug test and/or positive breath alcohol test screen prior first dose study ( Period 1 ) 16 . Positive test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) screen 17 . Any history presence alcoholism drug substance abuse define Investigator 18 . A history hypersensitivity idiosyncratic reaction testosterone , octisalate , PEG 200 , IPA , sunscreens , alcoholbased skin product Intrinsa® 19 . Use prescription ( except estrogen replacement therapy ) overthecounter ( OTC ) medication , within 30 day prior first dose study . Up 2 g per day acetaminophen allow discretion Investigator 20 . Use drug know clinical significance inhibit induce liver enzyme involve drug metabolism [ CYP P450 ] ) within 30 day prior first dose study . Use systemic corticosteroid within 30 day prior first dose study 21 . Blood donation significant blood loss within 56 day prior first dose study . Any contraindication blood sample 22 . Plasma donation within 7 day prior first dose study 23 . Currently use history androgen use within 6 month prior screen , use dehydroepiandrosterone ( DHEA ) &gt; /= 25 mg per day , St. John 's Wort within 4 week prior baseline . Due large number herbal remedy available , herbal supplement review Sponsor screen 24 . Currently use estratest ( esterified estrogens methyltestosterone ) 25 . Use investigational drug within 30 day six halflives , whichever longer , prior first dose study 26 . Clinical judgment Investigator subject participate study 27 . Involvement plan conduct study ( applies VIVUS designee staff , staff investigational site )</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>postmenopausal</keyword>
	<keyword>hormone replacement therapy</keyword>
</DOC>